Back to results
US 2026/0183301 A1Published application
Treating diseases and disorders with irak4-modifying compounds
AssigneeCuris, Inc.
InventorsAndrey Ugolkov, Robert Martell
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of treating diseases and disorders with IRAK4-modifying compounds, wherein said diseases and disorders are characterized by the presence of relevant biomarkers in a biological sample of a subject.
Claims318
A method of treating a disease or disorder in a subject, comprising:
- obtaining one or more of a biological sample(s) from the subject;
- analyzing the biological sample(s) for the presence of a first biomarker in a cell nucleus of the biological sample(s);
- and
- administering an IRAK4-modifying compound selected from an IRAK4 inhibitor or an IRAK4 degrader to the subject if the presence of the first biomarker is detected in the cell nucleus of the biological sample(s);
- wherein the first biomarker is selected from IRAK4, NF-κB p-p65, NF-κB p-p50, p-IRAK1, FLT3, and MYD88.
2 more elements
A method of treating a disease or disorder in a subject, comprising:
- obtaining one or more a biological sample(s) from the subject;
- measuring a sample expression level of a first biomarker in the biological sample(s);
- comparing the sample expression level of the first biomarker to a reference expression level of the first biomarker;
- administering an IRAK4-modifying compound selected from an IRAK4 inhibitor or an IRAK4 degrader to the subject if the sample expression level of the first biomarker is elevated in the sample(s) as compared to the reference expression level of the first biomarker;
- and
- wherein the first biomarker is selected from IRAK4, NF-κB p-p65, NF-κB p-p50, p-IRAK1, FLT3, and MYD88.
3 more elements
A method of treating a disease or disorder in a subject, comprising:
- obtaining one or more a biological sample(s) from the subject;
- measuring a sample expression level of a first biomarker in the biological sample(s);
- comparing the sample expression level of the first biomarker to a reference expression level of the first biomarker;
- analyzing the biological sample(s) for the presence of the first biomarker in a cell nucleus of the biological sample(s);
- and
- administering an IRAK4-modifying compound selected from an IRAK4 inhibitor or an IRAK4 degrader to the subject only if:
- the presence of the first biomarker is detected in the cell nucleus of the biological sample(s);
- and
- the sample expression level of the first biomarker is elevated in the sample(s) as compared to the reference expression level of the first biomarker;
- wherein the first biomarker is selected from IRAK4, NF-κB p-p65, NF-κB p-p50, p-IRAK1, FLT3, and MYD88.
7 more elements
The method of any one of claims 85-91, wherein the value is obtained from blood.
Dependencies are inferred from the claim text.